Guardant Health Inc (GH) — Titan Protect Analysis

Guardant Health Inc

Healthcare · ·

$125.61

Data: 2026-06-03

✓ ETHICAL PASS

NARROW MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$17.1B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-221.75

Based on estimated future earnings — lower means cheaper

Rev Growth

+48.3%

Year-over-year revenue change

Profit Margin

-40.1%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$130.00

+3% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 21 analysts covering this stock

About Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling t

https://guardanthealth.com

Country: United States Employees: 2,490 Industry: Diagnostics & Research

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.479

Excellent risk-adjusted returns

Kelly Fraction

0.1168

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

2.423

Returns exceed worst-case losses — strong risk profile

Annual Return

107.4%

Historical annualised return based on price data

Max Drawdown

-44.3%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.49

Moves slightly more than the broader market

52W High

$133.97

6% below the year high

52W Low

$40.35

211% above the year low

Avg Volume

2,133,017

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-3.40

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

64.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-40.2%

Profit from core operations before interest and tax

Free Cash Flow

$-85,448,128

Negative — the business is spending more than it generates

Revenue (TTM)

$1.1B

Total revenue over the last 12 months

Net Income

$-433,192,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$190.00

Target Median

$130.00

Target Low

$90.00

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
30 Apr2026	Dave McCormick	Republican	sell	100K–250K
30 Apr2026	Dave McCormick	Republican	sell	100K–250K
30 Apr2026	Dave McCormick	Republican	sell	100K–250K
2025-04-24	John Fetterman	Democrat	Purchase	1K–15K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go